The Study Of Remazolam Combined With Sufentanil And Propofol On Painless Gastroscopy: A Randomized Controlled Trial.

Abstract

Abstract Background Gastroscopy is one of the most commonly used diagnostic modalities for upper gastrointestinal disorders. Remazolam besylate, a new type of ultra-short-acting benzodiazepine drug, has been less studied in gastroscopy. In this study, we studied the efficacy and safety of remazolam combined with propofol for painless gastroscopy. Methods This was a single-center, placebo-controlled randomized trial. One hundred patients undergoing painless gastroscopy were included in this study and randomly divided into two groups (n = 50 per group): the control group (Con group) and the remazolam group (Rem group). Sufentanil, remazolam, and propofol are used to anesthetize the patients, and then, the effects of different solutions on these patients are compared and analyzed. The patient's general condition, vital signs at different times, the dosage of propofol (mg) and additional times, complications, duration of gastroscopy (min), recovery time (min), residence time in the resuscitation room (min), and adverse reactions were recorded. Results Rem group SBP is more stable(P < 0.05); The number of additional propofol in Rem group was less(P < 0.05). The incidence of hypotension, bradycardia and dizziness was lower in Rem group, as well as the time of awakening and staying in the resuscitation room were shorter(P < 0.05). Conclusion Remazolam combined with sufentanil and propofol have less effect on hemodynamics in painless gastroscopy, and the patients have shorter awakening time.